Clinical implications and mechanism of complement C1q in polymyositis

Di Wu; Yan Cui; Yujia Cao; Yanjuan Wang; Jinhua Zhang; Yijing Guo; Baoyu Yuan

doi:10.1007/s12010-023-04692-7

Clinical implications and mechanism of complement C1q in polymyositis

Appl Biochem Biotechnol. 2023 Aug 25. doi: 10.1007/s12010-023-04692-7. Online ahead of print.

Authors

Di Wu^#¹, Yan Cui^#², Yujia Cao¹, Yanjuan Wang¹, Jinhua Zhang¹, Yijing Guo¹, Baoyu Yuan³

Affiliations

¹ Department of Neurology, Affiliated Zhongda Hospital, Neuropsychiatric Institute, School of Medicine, Southeast University, No. 87, Dingjiaqiao, Gulou District, Nanjing, 210003, Jiangsu, China.
² Department of Anesthesiology, Chest Branch of Nanjing Brain Hospital, Nanjing, 210000, Jiangsu, China.
³ Department of Neurology, Affiliated Zhongda Hospital, Neuropsychiatric Institute, School of Medicine, Southeast University, No. 87, Dingjiaqiao, Gulou District, Nanjing, 210003, Jiangsu, China. yuanby1978@163.com.

^# Contributed equally.

PMID: 37624510
DOI: 10.1007/s12010-023-04692-7

Abstract

Polymyositis (PM) is the most common autoimmune disease in neurology and among muscle disorders; it is of great significance to thoroughly understand the mechanism of PM to find new diagnosis and treatment methods. This research intends to elucidate the clinical implications and mechanisms of complement C1q in polymyositis (PM). One hundred fifteen PM patients (research group, RG) and 120 healthy subjects (control group, CG) who visited our hospital between March 2017 and March 2020 were selected. Peripheral blood C1q and creatine kinase (CK) levels of both groups were measured, and their correlations with clinical symptoms and prognostic recurrence of PM. Additionally, to further understand the mechanism of action of C1q in PM, we purchased BALB/c mice and grouped them as follows: control group with normal feeding, PM group with PM modeling, intervention group with PM modeling, and intraperitoneal injection of gC1qR monoclonal antibody 60.11, a C1q protein receptor. Inflammatory factors and muscle histopathology were detected in all groups of mice. Finally, rat macrophages (mø) were isolated, and changes in the biological behavior of mø were observed after silencing the expression of gC1qR. Serum C1q and CK were both higher in RG than in CG, with favorable diagnostic effects on PM (P < 0.05). C1q and CK increased in symptomatic anti-ribonuclear protein antibody (RNP)-positive patients but decreased in anti Jo-1 antibody (Jo-1)- and anti-neutrophil cytoplasmic antibody (ANCA)-positive patients (P < 0.05). PM mice were observed with elevated gC1qR, while model mice exhibited severe infiltration of inflammatory cells in muscle tissue, increased pro-IFs, and reduced anti-IFs, and the animals in the intervention group showed improved conditions (P < 0.05). Finally, it was found that CD68, CD86 protein, and invasion capacity of gC1qR-sh-transfected cells decreased, while CD206 and CD163 increased (P < 0.05). C1q is elevated in PM and is strongly linked to the pathological process of PM. Inhibition of gC1qR expression reduced inflammatory infiltration in PM mice.

Keywords: Analysis of clinical significance; Complement C1q; Macrophage polarization; PI3K/AKT signaling pathway; Polymyositis.